You Are Not Alone! Find Support
+1 877 560 8035
info@melanomanetwork.ca
Strides for Melanoma
COVID-19 Update
About Melanoma
What is Melanoma?
Types of Melanoma
Melanoma Stats and Facts
How to Prevent Melanoma
How To Detect Melanoma
Melanoma Risk Factors
Non-Melanoma Skin Cancer
Basal Cell Carcinoma
What is Basal Cell Carcinoma
How is BCC treated?
Basal Cell Carcinoma Support Services
cutaneous Squamous Cell Carcinoma
About cSCC
Causes and Risk Factors of cSCC
What does cSCC look like
How is cSCC diagnosed?
How Does my Doctor Choose my Treatment?
How is cSCC treated?
Drug Therapy cemiplimab (Libtayo)
Questions to Ask Your Doctors
cSCC Cancer Support Services
CSCC Resources
Sun Safety
3 Ways to Block the Rays
Sun Safety
Sun Myths
Top 10 Sun Safety Myths Quiz
Tanning Beds
Winter Sun Awareness
Sunscreen Information
IPSOS Sun Safety Survey
Sunscreen Information
Canadian Sun Safety Council
About Canadian Sun Safety Council
Skin Cancer Facts
Sun Safety
Sun Myths
Sun Safety Research
Events
Patient Stories
News & Events
Blog
Latest News and Research
Fundraising Events
Strides for Melanoma
Soiree to End Skin Cancer
Fundraising Third Party Events
Calendar of Events
Melanoma Information Sessions
Melanoma Information Sessions
Toronto Melanoma Information Session
Melanoma Videos Information Session Video Library
Melanoma Support Groups
Aurora Melanoma Support Group
Calgary Melanoma Support Group
Oakville Melanoma Support Group
Oshawa Melanoma Support Group
Melanoma Newsletter – Melanoma Patient Connection
MNC Videos
Diagnosis & Treatment Information
Skin Biopsy
Diagnosing Melanoma
Diagnosing Melanoma – Pathology Report
Surgical tests prior to final staging – Melanoma Biopsys
Melanoma Diagnostic Tests
Staging Melanoma
Stages 0 – IV
Treating Melanoma
Surgery
Chemotherapy
Radiation
Immunotherapies
Targeted Therapy
Melanoma Drug Therapies in Canada
dabrafenib (Tafinlar) + trametinib (Mekinist)
cobimetinib (Cotellic) + vemurafenib (Zelboraf)
Ipilimumab (Yervoy)
Pembrolizumab (Keytruda)
Nivolumab (Opdivo)
Dabrafenib (Tafinlar)
nivolumab (Opdivo) + ipilimumab (Yervoy)
Trametinib (Mekinist)
Vemurafenib (Zelboraf)
Adjuvant Therapy
Melanoma Recurrence
Clinical Trials
Melanoma Treatment Centres and Practitioners
Questions to Ask Your Doctor
Lymphedema for the Melanoma Patient
Support & Resources
Melanoma Support Services
Peer to Peer Melanoma Support Program
Melanoma Phone and Email Support
Melanoma Support Groups
Melanoma Information Sessions
Caregiver Resources
Melanoma Patient Stories
Melanoma Forum
MNC Publications
MNC Publications
Melanoma Newsletter – Melanoma Patient Connection
Other Publications
Uveal Melanoma
Uveal Melanoma Resources
Ocular Melanoma Webinar
Uveal Melanoma Patient Stories
Questions To Ask Your Doctor Uveal Melanoma
Uveal Patient Forum
Uveal Melanoma Support
Dealing with A Diagnosis
Managing Life with Melanoma
Finding the Right Doctor
Questions to Ask Your Doctor
Glossary of Terms
Melanoma Videos Information Session Video Library
MNC Videos
Melanoma Patient Stories
Discussion Forum
Login
Register
Logout
About MNC
About the Melanoma Network of Canada
MNC Board of Directors
About Canadian Sun Safety Council
Screen Me Sun Aware Camp Program
DONATE
Your Donations in Action
MNC Affiliate Partners
MNC Corporate Partners
Volunteer
Contact Us
DONATE
NEW! 50/50 Raffle
Personal Giving
In Memory & In Honor Donation
Gift Registries
Legacy Giving
Corporate Giving
Special Events
MNC Affiliate Partners
MNC Corporate Partners
Your Donations in Action
Melanoma Research
Basal Cell Carcinoma (BCC)
Viewing topic 1 (of 1 total)
Topic
Voices
Posts
Last Post
Important Survey for Basal Cell Carcinoma Patients
Started by:
Melanoma Network of Canada
0
1
2 months ago
Melanoma Network of Canada
Viewing topic 1 (of 1 total)
You must be logged in to create new topics.
Log In
Username:
Password:
Keep me signed in
Log In
Forum HOME
Account
Login
Register
Logout
Create a new Forum Topic
Recent Topics
Search Forums
Search for:
Recent Topics
Important Survey for Basal Cell Carcinoma Patients
Connect with our online community
Virtual Melanoma Patient Support Group
Libtay (cemiplimab) Receives Positive Recommendation from the pan-Canadian Oncology Drug Review Expert Review Committee for the Treatment of Metastatic Cutaneous Squamous Cell Carcinoma
Concerned with questions seeking advice
Menu
